Eli Lilly (NY:LLY)

The mid-cap biotech could become a notable player in the industry's hottest therapeutic area.

Topics Stocks

Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029 ↗

November 27, 2025

Eli Lilly’s Stock Price Has Fattened Up Like a Thanksgiving Turkey. Time to (Options) Collar That Green!

November 27, 2025

As Eli Lilly makes history by joining the $1 trillion club, here’s how you can position for its next move.

It's not only tech companies that can get to that market valuation.

Prediction: This Growth Stock Could Hit a $2 Trillion Valuation by 2031 ↗

November 27, 2025

JPMorgan Says 2027 Medicare Drug Prices Signal Up To 40% Cuts Ahead — Novo Nordisk And Teva Stand Out As Top Targets ↗

November 26, 2025

JPMorgan said the implied net impact aligns with recent commentary from Novo Nordisk, Teva and AbbVie during earnings season.

Via Stocktwits

Topics Economy Government

Stock Split Watch: Is Eli Lilly Next? ↗

November 26, 2025

The stock recently reached beyond $1,000.

New York, NY – November 26, 2025 – U.S. stock markets are surging, with Wall Street poised to extend a remarkable winning streak as investors enthusiastically price in aggressive interest rate cuts by...

U.S. Stocks Extend Winning Streak as Wall Street Bets on Dovish Fed Pivot

November 26, 2025

AbbVie has outperformed the Nasdaq over the past year, and analysts are moderately optimistic about the stock’s prospects.

Topics Artificial Intelligence Bonds Economy

Is AbbVie Stock Outperforming the Nasdaq?

November 26, 2025

Companies and investors see AI as a game-changing technology.

Topics Stocks

Could AI Infrastructure Spending Be the Next Gold Rush for Investors? ↗

November 26, 2025

The weight loss drug market may approach almost $100 billion by the end of the decade.

Topics Artificial Intelligence

Did Pfizer Just Say "Checkmate" to Novo Nordisk? ↗

November 26, 2025

Retail Traders Crown Novo Nordisk As Long-Term Weight Loss King — Even As Eli Lilly Hits $1T And Viking Fans Tout ‘M&A Prize’ ↗

November 25, 2025

Users pointed to emerging drug pipelines, GLP-1 expansion and rising M&A pressure across the sector.

Via Stocktwits

Q3 Rundown: Organon (NYSE:OGN) Vs Other Branded Pharmaceuticals Stocks

November 25, 2025

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Organon (NYSE:OGN) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Should You Buy the Massive Dip in Novo Nordisk Stock?

November 25, 2025

Novo’s failed Alzheimer’s bet sparked a sharp selloff, leaving investors debating whether this bruising dip is a bargain or not.

Good news from a GLP-1 receptor agonist clinical trial hit the market today.

Here's Why Novo Nordisk Stock Popped Today ↗

November 25, 2025

As November 25, 2025, unfolds, financial markets find themselves at a critical juncture, gripped by a pervasive debate that pits optimists against skeptics: are current market pullbacks merely a "Buy...

The Great Divide: Is the Market Offering a Dip or Signalling a Bear?

November 25, 2025

Though UnitedHealth Group has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Topics Artificial Intelligence Economy Stocks

Is UnitedHealth Group Stock Underperforming the Nasdaq?

November 25, 2025

Eli Lilly’s remarkable outperformance within the pharmaceutical sector hasn’t tempered enthusiasm, analysts are still strongly bullish on its long-term growth potential.

Topics Stocks

A Trillion-Dollar Pill: Eli Lilly Broke the Healthcare Ceiling ↗

November 25, 2025

Via MarketBeat

How Is Eli Lilly’s Stock Performance Compared to Other Pharmaceuticals?

November 25, 2025

This Healthcare Company Just Touched $1 Trillion in Market Cap. Should You Invest $1,000? ↗

Topics ETFs

November 24, 2025

The rapidly expanding market for GLP-1 drugs has added massively to Eli Lilly's market cap.

Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk ↗

Topics Government World Trade

November 24, 2025

Novo's trial setback tests GLP-1-heavy ETFs, highlighting concentration risks while Eli Lilly's diversified pipeline offers relative resilience.

Via Benzinga

Topics ETFs

US Stock Market Navigates AI Euphoria and Rate Cut Hopes Amidst Mounting Volatility

November 24, 2025

The US stock market as of late November 2025 presents a nuanced landscape of resilience and apprehension. While major indices have enjoyed robust year-to-date gains, largely propelled by the relentless...

Copenhagen, Denmark – November 24, 2025 – Novo Nordisk's (CPH: NOVO B) stock experienced a significant and immediate downturn today, plummeting by over 10% in early trading, following the announcement...

Topics Artificial Intelligence Economy Electric Vehicles

Novo Nordisk Shares Plunge as Alzheimer's Drug Trial Fails to Meet Primary Endpoint

November 24, 2025

Eli Lilly fell while Biogen jumped.

Biotech Valuations Rise as New Clinical Platforms Show Progress

November 24, 2025

Via Investor Brand Network

Biotech Valuations Rise as New Clinical Platforms Show Progress

November 24, 2025

From BioMedWire

Via GlobeNewswire

Novo Nordisk Dives As Ozempic Fails To Slow Alzheimer's; Lilly Falls, Biogen Jumps ↗

November 24, 2025

Via Investor's Business Daily

Eli Lilly & Co (NYSE:LLY) Presents a Compelling Case for Growth at a Reasonable Price ↗

November 24, 2025

Eli Lilly (LLY) presents strong growth at a reasonable price (GARP), with accelerating earnings and revenue supported by top-tier profitability.

Via Chartmill

1 Spectacular Warren Buffett-Approved Index Fund That Could Turn $500 Per Month Into $1 Million ↗

November 24, 2025

Investing in an S&P 500 index fund can be a great way to build long-term wealth.